The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials
Abstract
Objective The objective of this study was to assess the efficacy and tolerability of intravenous magnesium for the treatment of acute migraine in adults. Selection criteria Double-blind, randomized controlled trials of intravenous magnesium for acute migraine in adults. Data sources Cochrane Central Register of Controlled Trials, Medline, EMBASE, CINAHL, National Research Register Archive, ACP Journal Club, the US Government’s Clinical Trial Database, Conference Proceedings, and other sources. Results Overall, 1203 abstracts were reviewed and five randomized controlled trials totalling 295 patients were eligible for the meta-analyses. The percentage of patients who experienced relief from headache 30 min following treatment was 7% lower in the magnesium groups compared with the controls [pooled risk difference=−0.07, 95% confidence interval (CI)=−0.23 to 0.09]. The percentage of patients who experienced side-effects or adverse events was greater in the magnesium groups compared with controls by 37% (pooled risk difference=0.370, 95% CI=0.06–0.68). The percentage of patients who needed rescue analgesic medications was slightly lower in the control groups, but this was not significant (pooled risk difference=−0.021, 95% CI=−0.16 to 0.12). Conclusion The meta-analyses have failed to demonstrate a beneficial effect of intravenous magnesium in terms of reduction in pain relief in acute migraine in adults, showed no benefit in terms of the need for rescue medication and in fact…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 295 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.